Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
ACS Infectious Diseases · 14.07.2023 · 9 (7) · 1372-1386
DOI: 10.1021/acsinfecdis.3c00125 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 30.06.2023. Verfasst von Julia M Flynn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United State…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Novartis.
Abstract (Originalsprache)
Drugs that target the main protease (Mpro) of SARS-CoV-2 are effective therapeutics that have entered clinical use. Wide-scale use of these drugs will apply selection pressure for the evolution of resistance mutations. To understand resistance potential in Mpro, we performed comprehensive surveys of amino acid changes that can cause resistance to nirmatrelvir (Pfizer), and ensitrelvir (Xocova) in a yeast screen. We identified 142 resistance mutations for nirmatrelvir and 177 for ensitrelvir, many of which have not been previously reported. Ninety-nine mutations caused apparent resistance to both inhibitors, suggesting likelihood for the evolution of cross-resistance. The mutation with the strongest drug resistance score against nirmatrelvir in our study (E166V) was the most impactful resistance mutation recently reported in multiple viral passaging studies. Many mutations that exhibited inhibitor-specific resistance were consistent with the distinct interactions of each inhibitor in the substrate binding site. In addition, mutants with strong drug resistance scores tended to have reduced function. Our results indicate that strong pressure from nirmatrelvir or ensitrelvir will select for multiple distinct-resistant lineages that will include both primary resistance mutations that weaken interactions with drug while decreasing enzyme function and compensatory mutations that increase enzyme activity. The comprehensive identification of resistance mutations enables the design of inhibitors with reduced potential of developing resistance and aids in the surveillance of drug resistance in circulating viral populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States.
- Novartis Institute for Biomedical Research, Emeryville, California 94608, United States.
ORCID-Profile: Julia M Flynn, Nese Kurt Yilmaz, Celia A Schiffer
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- Novartis
Zitieren
APA
Flynn, J. M., Huang, Q. Y. J., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Yilmaz, N. K., Moquin, S. A., Dovala, D., Schiffer, C. A., & Bolon, D. N. A. (2023). Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infectious Diseases, 9(7), 1372-1386. https://doi.org/10.1021/acsinfecdis.3c00125
Vancouver
Flynn JM, Huang QYJ, Zvornicanin SN, Schneider-Nachum G, Shaqra AM, Yilmaz NK, et al. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infectious Diseases. 2023;9(7):1372-1386. doi:10.1021/acsinfecdis.3c00125
BibTeX
@article{Flynn2023,
author = {Flynn, Julia M and Huang, Qiu Yu J and Zvornicanin, Sarah N and Schneider-Nachum, Gila and Shaqra, Ala M and Yilmaz, Nese Kurt and Moquin, Stephanie A and Dovala, Dustin and Schiffer, Celia A and Bolon, Daniel N A},
title = {Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease},
journal = {ACS Infectious Diseases},
year = {2023},
volume = {9},
number = {7},
pages = {1372--1386},
doi = {10.1021/acsinfecdis.3c00125}
}
EUVIMED